NCT00346658

Magnesium Supplementation to Prevent Bone Loss

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 74 (planned)
• Sponsor: University of Tennessee · Academic / Other
• Sex: All
• Age: 55 Years – 75 Years
• Healthy volunteers: Accepted

Summary

Extreme magnesium deficiency is known to have an impact on the synthesis, secretion and/or action of calcium regulating hormones. Many older adults are at risk for less severe magnesium deficiency, since the majority of adults receive less than the Recommended Daily Allowance of magnesium. We hypothesize that magnesium supplementation will have a beneficial effect on calcium regulating hormones and markers of bone turnover.

Detailed description

This is a 12 month randomized, double-blind, placebo-controlled study of magnesium supplementation. Our hypothesis was that magnesium supplementation would decrease bone turnover markers and alter calcium-regulating hormones: parathyroid hormone and 1, 25 dihydroxyvitamin D. Male and female adults over 55 without with a T-score at the hip above -2 are randomized to magnesium 250 mg BID or identical placebo BID. At baseline, all participants had a bone mineral density (BMD) by DXA scan at the hip and spine, blood biomarkers of bone resorption and formation, and calcium regulating hormones. Participants were followed for 12 months, with repeat measurement of calcium regulating hormones and bone turnover markers.

Conditions

• Osteoporosis

Interventions

Type	Name	Description
DRUG	magnesium

Timeline

• Start date: 2002-07-01
• Completion: 2006-09-01
• First posted: 2006-06-30
• Last updated: 2008-12-15

Locations

1 site across 1 country: United States